In terms of fundamentals, Pfizer currently boasts a market capitalization of $132 billion. Over the last twelve months, the ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as ...

Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to ...

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued blue chip stocks to buy according to hedge funds. Analyst Tim Anderson ...

Pfizer PFE will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...

Shares of Pfizer Inc. PFE slid 2.18% to $23.29 Thursday, on what proved to be an all-around dismal trading session for the ...

Pfizer (PFE) and BioNTech (BNTX) lose bid to appeal a High Court ruling that issued Moderna (MRNA) a COVID-19 vaccine patent ...